- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03885167
Identification of Biomarkers in Spinocerebellar Ataxia 3 (SCA3)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will undergo a SARA exam, a lumbar puncture and a blood draw. A lumbar puncture is a procedure in which a small amount of the spinal fluid that surrounds the brain and spinal cord is removed by inserting a needle in the lower back. Participants will be asked not to eat or drink anything (water is acceptable) for at least 6 hours before the lumbar puncture visit. For this procedure, participants will be positioned lying on their side and curled up in a ball, or sitting up and bent forward, whichever is easier. Cushions will be used to enhance comfort. The lower back region will be cleaned and disinfected with an antiseptic iodine solution. The doctor will inject local anesthetic (lidocaine, 1%) into the skin of the lower back. This may produce a transient, mild burning sensation. A very small needle will be introduced into the skin and moved into fluid-filled space around the spinal nerves coming from the spinal cord. This may produce a pressure sensation. Approximately 2 tablespoons approximately 30 ml) of fluid will be collected. The needle will be removed and a band-aid applied over the needle insertion site. Participants will be asked to remain stationary, lying on flat for about ½ hour on a bed in the research clinic. Participants will be given something to eat and drink before leaving. Strenuous physical activity should be avoided for the next 24 hours. This includes lifting, bending, doing housework and gardening, or doing exercise such as jogging or bicycle riding. The SARA (Scale for the Assessment and Rating of Ataxia) exam is a clinical scale that assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, fingerchase test, nose-finger test, fast alternating movements and heel-shin test, and takes approximately 15 minutes to complete.
The study also involves a single collection of about 3.5 tablespoons (approximately 50 ml) of blood. This blood draw may take place during a regularly scheduled visit to the neurology clinic or at the research appointment.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Contact
- Name: Frank Ferrari, BS
- Phone Number: 734-232-2352
- Email: frankfer@med.umich.edu
Study Contact Backup
- Name: Hayley McLoughlin, PhD
- Phone Number: 734-763-3511
- Email: hayleymc@med.umich.edu
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
•Confirmed Genetic Testing of SCA3 or Healthy Volunteers
Exclusion Criteria:
People with:
- unstable thyroid
- unstable intestinal/stomach issues
- unstable heart issues
- unstable liver issues
- unstable kidney issues
- unstable lung issues
- unstable hormone issues
- unstable mental disorders at screening
- a tumor or evidence of having a tumor
- a chronic infection or any severe acute infection within 3 months prior to screening
People who:
- Take anti-coagulants and NSAIDs
- Have started any investigational medications in the last month
- Women who are pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Affected Individuals with Known SCA3
In order to be eligible for this cohort, participants must have confirmed genetic testing results for Spinocerebellar Ataxia Type 3.
|
No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
|
Healthy Individual Control Subjects
In order to be eligible for this cohort, subjects must not have a diagnosis of Spinocerebellar Ataxia Type 3 and no major medical issues including but not limited to conditions that would cause an unsafe specimen collection.
|
No interventions take place as part of study participation- only specimen collection occurs for both cohorts.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Ataxin 3 Levels in Cerebrospinal Fluid Specimens
Time Frame: 4 Hours
|
A lumbar puncture is performed to collect CSF.
|
4 Hours
|
Change in Ataxin 3 Levels in Blood Plasma Specimens
Time Frame: 4 Hours
|
A single blood draw is completed.
|
4 Hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Henry Paulson, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Neurodegenerative Diseases
- Dyskinesias
- Spinal Cord Diseases
- Heredodegenerative Disorders, Nervous System
- Cerebellar Diseases
- Ataxia
- Cerebellar Ataxia
- Spinocerebellar Ataxias
- Spinocerebellar Degenerations
- Machado-Joseph Disease
Other Study ID Numbers
- HUM00121991
- U01NS106670 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinocerebellar Ataxia Type 3
-
University of FloridaAcorda TherapeuticsCompletedSpinocerebellar Ataxias Type 1 | Spinocerebellar Ataxias Type 2 | Spinocerebellar Ataxias Type 3 | Spinocerebellar Ataxias Type 6United States
-
Cadent TherapeuticsWithdrawnSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8 | Spinocerebellar Ataxia Type 17 | ARCA1 - Autosomal Recessive...United States
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxias | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 10 | Spinocerebellar Ataxia Type 7 | Spinocerebellar Ataxia Type 8United States, China
-
Biohaven Pharmaceuticals, Inc.Active, not recruitingSpinocerebellar Ataxias | Spinocerebellar Ataxia Genotype Type 1 | Spinocerebellar Ataxia Genotype Type 2 | Spinocerebellar Ataxia Genotype Type 3 | Spinocerebellar Ataxia Genotype Type 6 | Spinocerebellar Ataxia Genotype Type 7 | Spinocerebellar Ataxia Genotype Type 8 | Spinocerebellar Ataxia Genotype...United States
-
Teachers College, Columbia UniversityActive, not recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | Spinocerebellar Ataxia Type 7United States
-
Sclnow Biotechnology Co., Ltd.Not yet recruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6
-
National University of MalaysiaRadboud University Medical CenterRecruiting
-
University of California, Los AngelesActive, not recruitingSpinocerebellar Ataxias | Spinocerebellar Ataxia 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6 | MSA-CUnited States
-
University of FloridaUniversity of California, Los Angeles; National Ataxia FoundationRecruitingSpinocerebellar Ataxia Type 3 | Spinocerebellar Ataxia Type 1 | Spinocerebellar Ataxia Type 2 | Spinocerebellar Ataxia Type 6United States
-
BiogenTerminatedSpinocerebellar Ataxia Type 3United States, Netherlands, Israel, Portugal, United Kingdom, Germany
Clinical Trials on Specimen Collection
-
First Hospital of China Medical UniversityThe Second Hospital of Shandong University; The First People's Hospital of... and other collaboratorsRecruiting
-
University of California, San FranciscoNational Cancer Institute (NCI)RecruitingCancerUnited States
-
Baptist Health South FloridaNico Corporation; Miami Cancer InstituteNot yet recruitingGlioblastoma | Glioblastoma Multiforme | GliosarcomaUnited States
-
Mayo ClinicRecruitingCerebellar Ataxia | Spinocerebellar Ataxias | Nucleotide Repeat DiseaseUnited States
-
Winthrop University HospitalCompletedType 2 Diabetes | Diabetic Foot UlcerUnited States
-
University of California, San FranciscoCompletedMaxillary SinusitisUnited States
-
Winthrop University HospitalCompleted
-
Nova Mentis Life Science CorpFourthWall TestingRecruitingAutism Spectrum Disorder | Fra(X) SyndromeUnited States
-
National Alliance for Sickle Cell CentersBeam Therapeutics Inc.RecruitingSickle Cell TraitUnited States
-
University of North Carolina, Chapel HillNational Institutes of Health (NIH)Active, not recruitingEosinophilic EsophagitisUnited States